← All trials
NCT04644315
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 4, 2021
- Primary completion
- Dec 1, 2025
- Completion date
- Dec 1, 2025
- First posted
- Nov 25, 2020
- Last posted
- Dec 24, 2020
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
- Thyroid Cancer, Papillary
- Brain Neoplasms
- Bronchial Neoplasms
- Carcinoma, Bronchogenic
- Central Nervous System
- Colonic Diseases
- Digestive System Diseases
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Gastrointestinal Neoplasms
- Head and Neck Neoplasms
- Intestinal Diseases
- Intestinal Neoplasms
- Melanoma
- Neoplasms
- Neoplasms by Site
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Respiratory Tract Diseases
- Respiratory Tract Neoplasms
- Salivary Gland Neoplasms
- Sarcoma
- Thoracic Neoplasms
- Thyroid Neoplasms
- Colorectal Neoplasms
- Lymphoma, Large-Cell, Anaplastic
- Cholangiocarcinoma
- Neuroendocrine Tumors
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.